Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company.
A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Vuzix Corp | Paul Travers | Director, President and CEO | Other type of transaction at price $ 0.00 per share. | 02 Jan 2025 | 3,260,000 | 0 | - | - | Options (Right to Buy) | |
| Vuzix Corp | Paul Travers | Director, President and CEO | Other type of transaction at price $ 0.00 per share. | 02 Jan 2025 | 3,010,000 | 250,000 | - | - | Options (Right to Buy) | |
| Atlantic Intl Corp | Jeffrey M. Jagid | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 2,885,856 | 2,885,856 | - | - | Restricted Stock Units | |
| Atlantic Intl Corp | Jeffrey M. Jagid | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 02 Jan 2025 | 2,885,856 | 6,621,025 | - | 0.0 | 289 | Common Stock, $.00001 par value |
| Ocugen Inc | Shankar Musunuri | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 1,827,485 | 1,827,485 | - | - | Option (Right to Buy) | |
| Vuzix Corp | Grant Russell | Director, CFO | Other type of transaction at price $ 0.00 per share. | 02 Jan 2025 | 1,750,000 | 0 | - | - | Options (Right to Buy) | |
| Vuzix Corp | Grant Russell | Director, CFO | Other type of transaction at price $ 0.00 per share. | 02 Jan 2025 | 1,625,000 | 125,000 | - | - | Options (Right to Buy) | |
| ATAI Life Sciences N.V. | Gerd Kochendoerfer | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 1,450,000 | 1,450,000 | - | - | Stock Option | |
| Ocugen Inc | Huma Qamar | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 1,145,468 | 1,145,468 | - | - | Option (Right to Buy) | |
| TeraWulf Inc | Paul B. Prager | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 1,100,000 | 1,994,000 | - | - | Common stock, $0.001 par value per share | |
| TeraWulf Inc | Patrick A. Fleury | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 1,000,000 | 3,770,189 | - | - | Common stock, $0.001 par value per share | |
| TeraWulf Inc | Paul B. Prager | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 1,000,000 | 1,000,000 | - | - | Performance-Based Restricted Stock Units | |
| TeraWulf Inc | Nazar M. Khan | Director, Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 1,000,000 | 14,026,884 | - | - | Common stock, $0.001 par value per share | |
| TeraWulf Inc | Kerri M. Langlais | Director, Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 1,000,000 | 4,013,159 | - | - | Common stock, $0.001 par value per share | |
| Silence Therapeutics PLC (ADR) | Craig A. Tooman | Director, President and CEO | 02 Jan 2025 | 900,000 | 900,000 | - | - | Employee Share Option (Right to Buy) | ||
| Taysha Gene Therapies Inc | Sean P. Nolan | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 892,500 | 2,078,358 | - | 0 | Common Stock | |
| Taysha Gene Therapies Inc | Sean P. Nolan | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 892,500 | 892,500 | - | - | Employee Stock Option (right to buy) | |
| TeraWulf Inc | Nazar M. Khan | Director, Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 800,000 | 800,000 | - | - | Performance-Based Restricted Stock Units | |
| ARS Pharma Inc | Richard E. Lowenthal | Director, PRESIDENT AND CEO, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 767,600 | 767,600 | - | - | Stock option (right to buy) | |
| ARS Pharma Inc | Sarina Tanimoto | CHIEF MEDICAL OFFICER, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 767,600 | 767,600 | - | - | Stock Option (right to buy) | |
| Robinhood Markets Inc (Class A) | Vladimir Tenev | Director, Chief Executive Officer | 02 Jan 2025 | 750,000 | 47,323,144 | - | - | Class B Common Stock | ||
| Robinhood Markets Inc (Class A) | Vladimir Tenev | Director, Chief Executive Officer | 02 Jan 2025 | 750,000 | 750,000 | - | - | Class A Common Stock | ||
| Robinhood Markets Inc (Class A) | Vladimir Tenev | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 39.16 per share. | 02 Jan 2025 | 750,000 | 0 | - | 39.2 | 29,372,100 | Class A Common Stock |
| Ocugen Inc | Arun Upadhyay | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 730,994 | 730,994 | - | - | Option (Right to Buy) | |
| Anixa Biosciences Inc | Amit Kumar | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 700,000 | 700,000 | - | - | Employee Stock Option | |
| Ventyx Biosciences Inc | Raju S. Mohan | Director, CEO AND PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 700,000 | 700,000 | - | - | Stock Option (Right to Buy) | |
| NuScale Power Corp (Class A) | John L. Hopkins | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.41 per share. | 02 Jan 2025 | 664,568 | 699,243 | - | 3.4 | 2,266,177 | Class A Common Stock |
| NuScale Power Corp (Class A) | John L. Hopkins | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 18.04 per share. | 02 Jan 2025 | 664,568 | 34,675 | - | 18.0 | 11,988,807 | Class A Common Stock |
| NuScale Power Corp (Class A) | John L. Hopkins | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2025 | 664,568 | 664,568 | - | - | Employee Stock Option (right to buy) | |
| Kura Oncology Inc | Troy E. Wilson | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 625,000 | 625,000 | - | - | Option to purchase common stock | |
| Evolv Tech Holdings Inc (Class A) | John Kedzierski | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 621,000 | 621,000 | - | - | Restricted Stock Units | |
| Evolv Tech Holdings Inc (Class A) | John Kedzierski | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 621,000 | 621,000 | - | - | Restricted Stock Units | |
| TeraWulf Inc | Paul B. Prager | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 02 Jan 2025 | 608,300 | 1,385,700 | - | - | Common stock, $0.001 par value per share | |
| ORIC Pharma Inc | Jacob M. Chacko | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 600,000 | 600,000 | - | - | Stock Option (right to buy) | |
| Design Therapeutics Inc | Pratik Shah | Director, President, CEO and Chairperson | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 600,000 | 600,000 | - | - | Stock option (right to buy) | |
| Werewolf Therapeutics Inc | Daniel J. Hicklin, | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 592,690 | 592,690 | - | - | Stock Option (right to buy) | |
| Monte Rosa Therapeutics Inc | Markus Warmuth | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 575,000 | 575,000 | - | - | Stock Option (Right to Buy) | |
| Tempest Therapeutics Inc | Stephen R. Brady | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 550,000 | 550,000 | - | - | Employee Stock Option (right to buy) | |
| TeraWulf Inc | Nazar M. Khan | Director, Chief Technology Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 02 Jan 2025 | 546,131 | 13,480,753 | - | - | Common stock, $0.001 par value per share | |
| LXP Industrial Trust | T. Wilson Eglin | Director, Chairman, CEO and President | Grant, award, or other acquisition of securities at price $ 8.01 per share. | 02 Jan 2025 | 539,326 | 3,489,617 (1%) | 0% | 8.0 | 4,320,001 | Common Shares |
| TeraWulf Inc | Kerri M. Langlais | Director, Chief Strategy Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 02 Jan 2025 | 539,263 | 3,473,896 | - | - | Common stock, $0.001 par value per share | |
| 60 Degrees Pharma Inc | Geoffrey S. Dow | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 525,000 | 525,000 | - | - | Stock Option (Right to Buy) | |
| Dropbox Inc (Class A) | Andrew W. Houston | Director, Chief Executive Officer, Ten Percent Owner | 02 Jan 2025 | 500,323 | 500,323 (0%) | 0% | 0 | Class A Common Stock | ||
| Dropbox Inc (Class A) | Andrew W. Houston | Director, Chief Executive Officer, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 29.65 per share. | 02 Jan 2025 | 500,323 | 0 (0%) | 0% | 29.7 | 14,836,378 | Class A Common Stock |
| Dropbox Inc (Class A) | Andrew W. Houston | Director, Chief Executive Officer, Ten Percent Owner | 02 Jan 2025 | 500,323 | 67,858,302 | - | - | Class B Common Stock | ||
| TeraWulf Inc | Paul B. Prager | Director, Chief Executive Officer | Other type of transaction at price $ 0.00 per share. | 02 Jan 2025 | 500,000 | 1,598,883 | - | - | Common stock, $0.001 par value per share | |
| Atlassian Corp (Class A) | Farquhar Scott | Director, Ten Percent Owner | 02 Jan 2025 | 484,828 | 49,004,024 | - | - | Class B Common Stock | ||
| Atlassian Corp (Class A) | Scott Farquhar | Director, Ten Percent Owner | 02 Jan 2025 | 484,828 | 484,828 (0%) | 0% | - | Class A Common Stock | ||
| Atlassian Corp (Class A) | Michael Cannon-Brookes | Director, CEO, Co-Founder, Ten Percent Owner | 02 Jan 2025 | 484,828 | 49,004,024 | - | - | Class B Common Stock | ||
| Atlassian Corp (Class A) | Michael Cannon-Brookes | Director, CEO, Co-Founder, Ten Percent Owner | 02 Jan 2025 | 484,828 | 484,828 (0%) | 0% | - | Class A Common Stock | ||
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 482,908 | 482,908 | - | - | Stock Options (right to buy) | |
| Summit Hotel Properties Inc | Mehulkumar Bhikhubhai Patel | Director | 02 Jan 2025 | 479,295 | 479,295 (0%) | 0% | 0 | Common Stock | ||
| Summit Hotel Properties Inc | Mehulkumar Bhikhubhai Patel | Director | 02 Jan 2025 | 479,295 | 0 | - | - | Partnership Units | ||
| Regenxbio Inc | Curran Simpson | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 478,606 | 478,606 | - | - | Stock Options (Right to buy) | |
| Regenxbio Inc | Curran Simpson | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 476,606 | 476,606 | - | - | Stock Options (Right to buy) | |
| Pearson PLC (ADR) | Omar P Abbosh | Executive Director,Chief Executive Officer | 02 Jan 2025 | 462,842 | 462,842 (0%) | 0% | 0 | Ords 0.25p | ||
| Oramed Pharma Inc | Kidron Nadav | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 433,500 | 2,259,598 (12%) | 2% | - | Common Stock | |
| Taysha Gene Therapies Inc | Kamran Alam | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 431,000 | 1,271,937 | - | 0 | Common Stock | |
| Taysha Gene Therapies Inc | Kamran Alam | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 431,000 | 431,000 | - | - | Employee Stock Option (right to buy) | |
| Equillium Inc | Bruce D. Steel | Director, President and CEO, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 410,000 | 410,000 | - | - | Employee Stock Option (right to buy) | |
| Palantir | Ryan Taylor | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2025 | 400,000 | 66,670 | - | - | Employee Stock Option (Right to buy) | |
| Palantir | Ryan Taylor | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.72 per share. | 02 Jan 2025 | 400,000 | 654,260 | - | 4.7 | 1,888,000 | Class A Common Stock |
| TeraWulf Inc | Patrick A. Fleury | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 02 Jan 2025 | 379,763 | 3,390,426 | - | - | Common stock, $0.001 par value per share | |
| Palo Alto | Arora Nikesh | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 33.08 per share. | 02 Jan 2025 | 376,670 | 1,463,074 (1%) | 0% | 33.1 | 12,461,524 | Common Stock |
| Palo Alto | Arora Nikesh | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2025 | 376,670 | 3,623,330 | - | - | Stock Option (right to buy) | |
| Silence Therapeutics PLC (ADR) | Rhonda L. Hellums | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 375,000 | 375,000 | - | - | Employee Share Option (Right to Buy) | |
| Ocugen Inc | Ramesh Ramachandran | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 350,146 | 350,146 | - | - | Option (Right to Buy) | |
| Anixa Biosciences Inc | Michael J. Catelani | President, COO & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 350,000 | 350,000 | - | - | Employee Stock Option | |
| Warby Parker Inc (Class A) | David Gilboa | Director, Co-Chief Executive Officer | 02 Jan 2025 | 338,004 | 350,310 | - | 0 | Class A Common Stock | ||
| Warby Parker Inc (Class A) | David Gilboa | Director, Co-Chief Executive Officer | 02 Jan 2025 | 338,004 | 5,587,470 | - | - | Class B Common Stock | ||
| Warby Parker Inc (Class A) | David Gilboa | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 25.14 per share. | 02 Jan 2025 | 337,904 | 12,406 | - | 25.1 | 8,494,907 | Class A Common Stock |
| BlackBerry Ltd | John J. Giamatteo | Director, CEO & President, Cybersecurity | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2025 | 335,277 | 541,367 (0%) | 0% | - | Common Shares | |
| BlackBerry Ltd | John J. Giamatteo | Director, CEO & President, Cybersecurity | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2025 | 335,277 | 670,553 | - | - | Restricted Share Units | |
| Taysha Gene Therapies Inc | Sukumar Nagendran | Director, President and Head of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 324,500 | 324,500 | - | - | Employee Stock Option (right to buy) | |
| Taysha Gene Therapies Inc | Sukumar Nagendran | Director, President and Head of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 324,500 | 1,222,343 | - | 0 | Common Stock | |
| Bicycle Therapeutics PLC (ADR) | Kevin Lee | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 308,000 | 308,000 | - | - | Employee Stock Option (right to buy) | |
| Immersion Corp | Eric B. Singer | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 300,000 | 2,132,345 (6%) | 0% | 0 | Common Stock | |
| Warby Parker Inc (Class A) | Neil Blumenthal | Director, Co-Chief Executive Officer | 02 Jan 2025 | 300,000 | 312,177 | - | 0 | Class A Common Stock | ||
| Warby Parker Inc (Class A) | Neil Blumenthal | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 25.14 per share. | 02 Jan 2025 | 300,000 | 12,177 | - | 25.1 | 7,542,000 | Class A Common Stock |
| Warby Parker Inc (Class A) | Neil Blumenthal | Director, Co-Chief Executive Officer | 02 Jan 2025 | 300,000 | 4,314,689 | - | - | Class B Common Stock | ||
| Vuzix Corp | Paul Travers | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 291,878 | 291,878 | - | - | Restricted Stock Unit | |
| Vuzix Corp | Paul Travers | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 291,878 | 291,878 | - | - | Restricted Stock Unit | |
| Silence Therapeutics PLC (ADR) | Steven Joseph Romano | EVP and Chief R&D Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 285,000 | 285,000 | - | - | Employee Share Option (Right to Buy) | |
| Janux Therapeutics Inc | David Campbell | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 283,500 | 283,500 | - | - | Stock option (right to buy) | |
| ARS Pharma Inc | Justin Chakma | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 274,100 | 274,100 | - | - | Stock option (right to buy) | |
| AMC Entertainment Holdings Inc (Class A) | Adam M. Aron | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2025 | 273,566 | 847,237 (1%) | 0% | 0 | Class A Common Stock | |
| Tempest Therapeutics Inc | Samuel Whiting | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 270,000 | 270,000 | - | - | Employee Stock Option (right to buy) | |
| Vuzix Corp | Peter Jameson | Chief Operating Officer | Other type of transaction at price $ 0.00 per share. | 02 Jan 2025 | 270,000 | 0 | - | - | Options (Right to Buy) | |
| Amicus Therapeutics Inc | Bradley L. Campbell | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 266,528 | 1,132,535 (0%) | 0% | 0 | Common Stock | |
| ARS Pharma Inc | Brian T. Dorsey | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 261,900 | 261,900 | - | - | Stock option (right to buy) | |
| ARS Pharma Inc | Richard E. Lowenthal | Director, PRESIDENT AND CEO, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 261,900 | 261,900 | - | - | Stock Option (right to buy) | |
| ARS Pharma Inc | Sarina Tanimoto | CHIEF MEDICAL OFFICER, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 261,900 | 261,900 | - | - | Stock option (right to buy) | |
| JBG SMITH Properties | W. Matthew Kelly | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 260,223 | 2,663,669 | - | - | AO LTIP | |
| Design Therapeutics Inc | Sean Jeffries | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 260,000 | 260,000 | - | - | Stock option (right to buy) | |
| MFA Fin Inc | Craig L. Knutson | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 257,604 | 1,439,013 | - | - | Phantom Shares | |
| Nuvectis Pharma Inc | Ron Bentsur | Director, Chairman & CEO, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 250,000 | 3,520,924 | - | 0 | Common Stock | |
| NewAmsterdam Pharma Co NV | Douglas F. Kling | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 250,000 | 250,000 | - | - | Option (right to buy) | |
| LXP Industrial Trust | T. Wilson Eglin | Director, Chairman, CEO and President | Sale or transfer of securities back to the company at price $ 8.01 per share. | 02 Jan 2025 | 246,914 | 2,950,291 (1%) | 0% | 8.0 | 1,977,781 | Common Shares |
| Ventyx Biosciences Inc | John M. Nuss | CHIEF SCIENTIFIC OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 245,000 | 245,000 | - | - | Stock Option (Right to Buy) | |
| Weatherford Intl PLC - Ordinary Shares - New | Girishchandra K. Saligram | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2025 | 237,529 | 0 | - | - | 2021 Program Performance Share Units | |
| Weatherford Intl PLC - Ordinary Shares - New | Girishchandra K. Saligram | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2025 | 237,529 | 238,335 (0%) | 0% | 0 | Ordinary Shares | |
| Palo Alto | Arora Nikesh | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 33.08 per share. | 02 Jan 2025 | 235,492 | 1,321,896 (1%) | 0% | 33.1 | 7,790,876 | Common Stock |
| Palo Alto | Arora Nikesh | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2025 | 235,492 | 3,387,838 | - | - | Stock Option (right to buy) | |
| Palantir | Ryan Taylor | See Remarks | Sale of securities on an exchange or to another person at price $ 74.96 per share. | 02 Jan 2025 | 230,544 | 200,981 | - | 75.0 | 17,280,979 | Class A Common Stock |
| Lexicon Pharma Inc | Scott M. Coiante | SVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 230,000 | 230,000 | - | - | Stock Option (Right to Buy) | |
| Palo Alto | Arora Nikesh | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 180.19 per share. | 02 Jan 2025 | 228,701 | 1,234,373 (1%) | 0% | 180.2 | 41,209,176 | Common Stock |
| FedEx | Frederick W. Smith | Director, Executive Chairman | Gift of securities by or to the insider at price $ 0.00 per share. | 02 Jan 2025 | 225,000 | 14,280,844 (5%) | 0% | 0 | Common Stock | |
| FedEx | Frederick W. Smith | Director, Executive Chairman | Gift of securities by or to the insider at price $ 0.00 per share. | 02 Jan 2025 | 225,000 | 1,127,018 (0%) | 0% | 0 | Common Stock | |
| CarPartscom Inc | David Meniane | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 225,000 | 225,000 | - | - | Restricted Stock Awards | |
| Arcellx Inc | Rami Elghandour | Director, SEE REMARKS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 223,964 | 223,964 | - | - | Restricted Stock Unit | |
| FedEx | Frederick W. Smith | Director, Executive Chairman | Gift of securities by or to the insider at price $ 0.00 per share. | 02 Jan 2025 | 223,400 | 903,618 (0%) | 0% | 0 | Common Stock | |
| Regenxbio Inc | Patrick J. Christmas | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 223,350 | 223,350 | - | - | Stock Options (Right to buy) | |
| Sempra Energy | Jeffrey Walker Martin | Director, Chairman, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 222,547 | 222,547 | - | - | Employee Stock Option (right to buy) | |
| NewAmsterdam Pharma Co NV | Ian Somaiya | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 220,000 | 220,000 | - | - | Option (right to buy) | |
| Unity Software Inc | Tomer Bar-Zeev | Director | Sale of securities on an exchange or to another person at price $ 24.95 per share. | 02 Jan 2025 | 219,210 | 3,678,936 | - | 25.0 | 5,469,290 | Common Stock |
| JBG SMITH Properties | W. Matthew Kelly | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 218,238 | 1,880,303 | - | - | LTIP Units | |
| Gaming and Leisure Properties Inc | Peter M. Carlino | Director, Chairman and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 214,940 | 6,084,110 (2%) | 0% | 0 | Common Stock | |
| AMC Entertainment Holdings Inc (Class A) | Adam M. Aron | Director, Chairman, President & CEO | 02 Jan 2025 | 210,526 | 421,053 | - | - | Restricted Stock Units | ||
| Capricor Therapeutics Inc | Linda Marban | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 210,000 | 210,000 | - | - | Stock Option (Right to Buy) | |
| Oramed Pharma Inc | Miriam Kidron | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 207,000 | 1,000,666 (5%) | 1% | - | Common Stock | |
| Amicus Therapeutics Inc | Ellen S. Rosenberg | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 203,825 | 203,825 | - | - | Stock Options (right to buy) | |
| ORIC Pharma Inc | Pratik S. Multani | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 202,500 | 202,500 | - | - | Stock Option (right to buy) | |
| ORIC Pharma Inc | Dominic G. Piscitelli | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 202,500 | 202,500 | - | - | Stock Option (right to buy) | |
| La Rosa Holdings Corp | Joseph La Rosa | Director, CEO, interim CFO, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 200,000 | 200,000 | - | - | Stock Option (Right to Buy) | |
| La Rosa Holdings Corp | Joseph La Rosa | Director, CEO, interim CFO, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 200,000 | 200,000 | - | - | Stock Option (Right to Buy) | |
| NewAmsterdam Pharma Co NV | William Jones | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 200,000 | 200,000 | - | - | Option (right to buy) | |
| NewAmsterdam Pharma Co NV | Johannes Jacob Pieter Kastelein | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 200,000 | 200,000 | - | - | Option (right to buy) | |
| Tempest Therapeutics Inc | Nicholas Maestas | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 200,000 | 200,000 | - | - | Employee Stock Option (right to buy) | |
| Oramed Pharma Inc | Joshua Hexter | COO & CBO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 194,500 | 706,333 (3%) | 1% | - | Common Stock | |
| UDR | Thomas W. Toomey | Director, Chairman and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 190,904 | 1,001,804 | - | - | Class 2 LTIP Units | |
| Oramed Pharma Inc | Avraham Gabay | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 188,000 | 358,040 (2%) | 1% | - | Common Stock | |
| Werewolf Therapeutics Inc | Randi Isaacs | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 187,500 | 187,500 | - | - | Stock Option (right to buy) | |
| Werewolf Therapeutics Inc | Daniel J. Hicklin, | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 185,652 | 185,652 | - | - | Stock Option (right to buy) | |
| Kura Oncology Inc | Kathleen Ford | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 185,000 | 185,000 | - | - | Option to purchase common stock | |
| Kura Oncology Inc | Francis Burrows | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 185,000 | 185,000 | - | - | Option to purchase common stock | |
| Protagonist Therapeutics Inc | Dinesh V. Patel | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 181,472 | 181,472 | - | - | Stock Option (right to buy) | |
| LXP Industrial Trust | T. Wilson Eglin | Director, Chairman, CEO and President | Grant, award, or other acquisition of securities at price $ 8.01 per share. | 02 Jan 2025 | 179,780 | 3,669,397 (1%) | 0% | 8.0 | 1,440,038 | Common Shares |
| Palantir | Ryan Taylor | See Remarks | Sale of securities on an exchange or to another person at price $ 73.97 per share. | 02 Jan 2025 | 177,995 | 431,525 | - | 74.0 | 13,167,127 | Class A Common Stock |
| Ocugen Inc | Shankar Musunuri | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.89 per share. | 02 Jan 2025 | 177,146 | 1,832,723 (3%) | 0% | 0.9 | 158,457 | Common Stock |
| ARS Pharma Inc | Kathleen D. Scott | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 176,700 | 176,700 | - | - | Stock option (right to buy) | |
| Palo Alto | Arora Nikesh | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2025 | 176,242 | 3,211,596 | - | - | Stock Option (right to buy) | |
| Palo Alto | Arora Nikesh | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 33.08 per share. | 02 Jan 2025 | 176,242 | 1,262,646 (1%) | 0% | 33.1 | 5,830,685 | Common Stock |
| Equillium Inc | Jason A. Keyes | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 175,000 | 175,000 | - | - | Employee Stock Option (right to buy) | |
| Equillium Inc | Stephen Connelly | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 175,000 | 175,000 | - | - | Employee Stock Option (right to buy) | |
| Equillium Inc | Christine Zedelmayer | Sr. Vice President and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 175,000 | 175,000 | - | - | Employee Stock Option (right to buy) | |
| Dyadic Intl Inc, DE | Mark A. Emalfarb | Director, President and CEO, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 172,000 | 172,000 | - | - | Stock Option | |
| Ventyx Biosciences Inc | John M. Nuss | CHIEF SCIENTIFIC OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 170,104 | 170,104 | - | - | Stock Option (right to buy) | |
| Cartesian Therapeutics Inc | Carsten Brunn | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 169,100 | 169,100 | - | - | Employee Stock Option (right to buy) | |
| LXP Industrial Trust | Brendan P. Mullinix | EVP & Chief Investment Officer | Grant, award, or other acquisition of securities at price $ 8.01 per share. | 02 Jan 2025 | 164,795 | 752,455 (0%) | 0% | 8.0 | 1,320,008 | Common Shares |
| Monte Rosa Therapeutics Inc | Sharon Townson | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 161,000 | 161,000 | - | - | Stock Option (Right to Buy) | |
| Monte Rosa Therapeutics Inc | Filip Janku | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 161,000 | 161,000 | - | - | Stock Option (Right to Buy) | |
| Monte Rosa Therapeutics Inc | Philip Nickson | Chief Business & Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 161,000 | 161,000 | - | - | Stock Option (Right to Buy) | |
| MFA Fin Inc | Craig L. Knutson | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 159,687 | 1,181,409 | - | - | Phantom Shares | |
| Easterly Government Properties Inc | Darrell W. Crate | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 159,671 | 159,671 | - | - | LTIP Units | |
| BlackBerry Ltd | John J. Giamatteo | Director, CEO & President, Cybersecurity | Sale of securities on an exchange or to another person at price $ 3.68 per share. | 02 Jan 2025 | 155,815 | 385,552 (0%) | 0% | 3.7 | 573,399 | Common Shares |
| Werewolf Therapeutics Inc | Chulani Karunatilake | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 153,129 | 153,129 | - | - | Stock Option (right to buy) | |
| ARS Pharma Inc | Alexander A. Fitzpatrick | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 152,300 | 152,300 | - | - | Stock option (right to buy) | |
| ARS Pharma Inc | Eric Karas | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 152,300 | 152,300 | - | - | Stock option (right to buy) | |
| Amicus Therapeutics Inc | Simon Nicolas Reade Harford | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 150,517 | 150,517 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Jeff Castelli | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 150,517 | 150,517 | - | - | Stock Options (right to buy) | |
| Nuvectis Pharma Inc | Enrique Poradosu | Chief Science & Business Off | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 150,000 | 1,656,319 | - | 0 | Common Stock | |
| Nuvectis Pharma Inc | Shay Shemesh | Chief Dev. & Ops. Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 150,000 | 1,643,068 | - | 0 | Common Stock | |
| Werewolf Therapeutics Inc | Timothy W. Trost | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 150,000 | 150,000 | - | - | Stock Option (right to buy) | |
| Werewolf Therapeutics Inc | Chulani Karunatilake | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 150,000 | 150,000 | - | - | Stock Option (right to buy) | |
| Nexgel Inc | Adam Levy | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 150,000 | 150,000 | - | - | Stock Options (right to buy) | |
| CarPartscom Inc | David Meniane | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 150,000 | 150,000 | - | - | Restricted Stock Awards | |
| Protagonist Therapeutics Inc | Dinesh V. Patel | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 149,800 | 558,255 (2%) | 0% | 0 | Common Stock | |
| Microchip Tech | Steve Sanghi | Director, CHAIR OF THE BOARD | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 148,133 | 148,133 | - | - | Restricted Stock Units | |
| Ventyx Biosciences Inc | Matthew Richard Moore | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 145,000 | 145,000 | - | - | Stock Option (Right to Buy) | |
| MFA Fin Inc | Bryan Wulfsohn | Pres. & Chief Invest. Ofcr. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 142,061 | 648,249 | - | - | Phantom Shares | |
| CarPartscom Inc | Michael Huffaker | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 140,000 | 140,000 | - | - | Restricted Stock Awards | |
| Design Therapeutics Inc | Julie Burgess | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 135,000 | 135,000 | - | - | Stock option (right to buy) | |
| Monte Rosa Therapeutics Inc | Jennifer Champoux | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 135,000 | 135,000 | - | - | Stock Option (Right to Buy) | |
| Werewolf Therapeutics Inc | Ellen Lubman | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 131,900 | 131,900 | - | - | Stock Option (right to buy) | |
| Halliburton | Jefferey A. Miller | Director, Director, President & CEO | Grant, award, or other acquisition of securities at price $ 27.73 per share. | 02 Jan 2025 | 130,323 | 855,926 (0%) | 0% | 27.7 | 3,613,857 | Common Stock |
| Microchip Tech | Steve Sanghi | Director, CHAIR OF THE BOARD | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 128,861 | 128,861 | - | - | Restricted Stock Units | |
| Monte Rosa Therapeutics Inc | Markus Warmuth | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 128,000 | 544,538 | - | - | Common Stock | |
| LXP Industrial Trust | James Dudley | EVP & Director of Asset Mgmt. | Grant, award, or other acquisition of securities at price $ 8.01 per share. | 02 Jan 2025 | 127,341 | 429,804 (0%) | 0% | 8.0 | 1,020,001 | Common Shares |
| LXP Industrial Trust | Nathan Brunner | EVP of Capital Markets | Grant, award, or other acquisition of securities at price $ 8.01 per share. | 02 Jan 2025 | 127,341 | 277,341 (0%) | 0% | 8.0 | 1,020,001 | Common Shares |
| Amicus Therapeutics Inc | David Michael Clark | Chief People Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 125,430 | 125,430 | - | - | Stock Options (right to buy) | |
| Myers Ind Inc | Aaron M. Schapper | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 125,000 | 125,000 | - | - | Stock Options | |
| Equillium Inc | Penny Tom | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 125,000 | 125,000 | - | - | Employee Stock Option (right to buy) | |
| CarPartscom Inc | Kals Subramanian | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 125,000 | 125,000 | - | - | Restricted Stock Awards | |
| AMC Entertainment Holdings Inc (Class A) | Adam M. Aron | Director, Chairman, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 02 Jan 2025 | 124,417 | 722,820 (1%) | 0% | 0 | Class A Common Stock | |
| Bicycle Therapeutics PLC (ADR) | Kevin Lee | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 123,200 | 504,064 | - | 0 | Ordinary Shares | |
| Vuzix Corp | Grant Russell | Director, CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 118,211 | 118,211 | - | - | Restricted Stock Unit | |
| Vuzix Corp | Grant Russell | Director, CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 118,211 | 118,211 | - | - | Restricted Stock Unit | |
| UDR | Joseph D. Fisher | President, CFO & CIO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 117,271 | 548,120 | - | - | Class 2 LTIP Units | |
| Microchip Tech | Steve Sanghi | Director, CHAIR OF THE BOARD | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 115,414 | 115,414 | - | - | Restricted Stock Units | |
| Amicus Therapeutics Inc | Ellen S. Rosenberg | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 112,495 | 490,272 (0%) | 0% | 0 | Common Stock | |
| Vuzix Corp | Peter Jameson | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 111,642 | 111,642 | - | - | Restricted Stock Unit | |
| Edison International | Pedro J. Pizarro | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 63.72 per share. | 02 Jan 2025 | 111,608 | 302,647 (0%) | 0% | 63.7 | 7,111,662 | Common Stock |
| Edison International | Pedro J. Pizarro | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2025 | 111,608 | 0 | - | - | Non-qualified Stock Options (Right to Buy) | |
| Palo Alto | Arora Nikesh | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 181.93 per share. | 02 Jan 2025 | 110,147 | 1,124,226 (1%) | 0% | 181.9 | 20,038,934 | Common Stock |
| Imax Corp | Richard Lewis Gelfond | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 109,518 | 109,518 | - | - | restricted share units | |
| Ventyx Biosciences Inc | Roy M. Gonzales | Senior VP, Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 109,200 | 109,200 | - | - | Stock Option (Right to Buy) | |
| DoorDash | Tony Xu | Director, CHIEF EXECUTIVE OFFICER, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.16 per share. | 02 Jan 2025 | 108,332 | 109,832 | - | 7.2 | 775,657 | Class A Common Stock |
| DoorDash | Tony Xu | Director, CHIEF EXECUTIVE OFFICER, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2025 | 108,332 | 1,644,152 | - | - | Stock Option (right to buy) | |
| Information Services Grp Inc | Michael P. Connors | Director, CHAIRMAN & CEO, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 107,692 | 107,692 | - | - | Performance Based RSUs | |
| BlackBerry Ltd | Tim Foote | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 104,712 | 104,712 | - | - | Restricted Share Units | |
| Regenxbio Inc | Stephen Pakola | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 103,698 | 103,698 | - | - | Stock Options (Right to buy) | |
| Palo Alto | Arora Nikesh | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 182.99 per share. | 02 Jan 2025 | 102,330 | 1,194,064 (1%) | 0% | 183.0 | 18,725,776 | Common Stock |
| Newmark Grp Inc (Class A) | Lutnick W. Howard | Director, Executive Chairman, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 101,133 | 1,710,467 | - | - | Newmark Holdings Exchangeable Limited Partnership Interests | |
| ORIC Pharma Inc | Jacob M. Chacko | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 100,000 | 100,000 | - | - | Restricted Stock Unit | |
| NewAmsterdam Pharma Co NV | Juliette Audet | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 100,000 | 100,000 | - | - | Option (right to buy) | |
| CarPartscom Inc | Ryan Lockwood | Chief Financial Officer | 02 Jan 2025 | 100,000 | 100,000 | - | - | Restricted Stock Awards | ||
| CarPartscom Inc | Ryan Lockwood | Chief Financial Officer | 02 Jan 2025 | 100,000 | 100,000 | - | - | Restricted Stock Awards | ||
| CarPartscom Inc | Kals Subramanian | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 100,000 | 100,000 | - | - | Restricted Stock Awards | |
| CarPartscom Inc | Michael Huffaker | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 100,000 | 100,000 | - | - | Restricted Stock Awards | |
| Cyclacel Pharma Inc | David Natan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 100,000 | 100,000 (0%) | 0% | - | Common Stock | |
| Regenxbio Inc | Curran Simpson | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 98,912 | 257,032 (0%) | 0% | 0 | Common Stock | |
| Palo Alto | Arora Nikesh | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 183.94 per share. | 02 Jan 2025 | 98,854 | 1,095,210 (1%) | 0% | 183.9 | 18,183,699 | Common Stock |
| Edison International | Pedro J. Pizarro | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 80.01 per share. | 02 Jan 2025 | 98,628 | 204,019 (0%) | 0% | 80.0 | 7,891,226 | Common Stock |
| Janux Therapeutics Inc | Byron Robinson | Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 98,000 | 98,000 | - | - | Stock option (right to buy) | |
| Payoneer Global Inc | Tsafi Goldman | Chief Legal & Regulatory Ofcr | Sale of securities on an exchange or to another person at price $ 10.07 per share. | 02 Jan 2025 | 96,350 | 741,748 | - | 10.1 | 970,245 | Common Stock |
| Palantir | David Glazer | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.72 per share. | 02 Jan 2025 | 96,273 | 389,684 | - | 4.7 | 454,409 | Class A Common Stock |
| Palantir | David Glazer | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2025 | 96,273 | 11,257 | - | - | Employee Stock Option (Right to buy) | |
| Regenxbio Inc | Olivier Danos | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 95,721 | 95,721 | - | - | Stock Options (Right to buy) | |
| UiPath Inc (Class A) | Ashim Gupta | COO & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.71 per share. | 02 Jan 2025 | 95,165 | 903,765 | - | 12.7 | 1,209,547 | Class A Common Stock |
| Weatherford Intl PLC - Ordinary Shares - New | Girishchandra K. Saligram | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 72.29 per share. | 02 Jan 2025 | 93,594 | 144,741 (0%) | 0% | 72.3 | 6,765,910 | Ordinary Shares |
| Gaming and Leisure Properties Inc | Peter M. Carlino | Director, Chairman and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 48.16 per share. | 02 Jan 2025 | 93,478 | 5,990,632 (2%) | 0% | 48.2 | 4,501,900 | Common Stock |
| Rallybio Corp | Martin W. Mackay | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 92,857 | 92,857 | - | - | Option (Right to Buy) | |
| Kura Oncology Inc | Teresa Brophy Bair | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 92,500 | 92,500 | - | - | Option to purchase common stock | |
| Kura Oncology Inc | Brian T. Powl | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 92,500 | 92,500 | - | - | Option to purchase common stock | |
| Kura Oncology Inc | Mollie Leoni | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 92,500 | 92,500 | - | - | Option to purchase common stock | |
| Palantir | David Glazer | See Remarks | Sale of securities on an exchange or to another person at price $ 72.83 per share. | 02 Jan 2025 | 91,397 | 298,287 | - | 72.8 | 6,656,809 | Class A Common Stock |
| Janux Therapeutics Inc | Zachariah McIver | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 91,000 | 91,000 | - | - | Stock option (right to buy) | |
| Silence Therapeutics PLC (ADR) | Iain Gladstone Ross | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 90,000 | 90,000 | - | - | Share Option (Right to Buy) | |
| MFA Fin Inc | Bryan Wulfsohn | Pres. & Chief Invest. Ofcr. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 88,063 | 506,188 | - | - | Phantom Shares | |
| CorMedix Inc | Elizabeth Hurlburt | EVP | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 87,500 | 132,897 (0%) | 0% | 0 | Common Stock | |
| CorMedix Inc | Beth Zelnick Kaufman | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 87,500 | 131,456 (0%) | 0% | 0 | Common Stock | |
| Bicycle Therapeutics PLC (ADR) | Santiago Arroyo | CHIEF DEVELOPMENT OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 87,000 | 87,000 | - | - | Employee Stock Option (right to buy) | |
| Bicycle Therapeutics PLC (ADR) | Michael Skynner | CHIEF TECHNOLOGY OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 87,000 | 87,000 | - | - | Employee Stock Option (right to buy) | |
| Bicycle Therapeutics PLC (ADR) | Alistair Milnes | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 87,000 | 87,000 | - | - | Employee Stock Option (right to buy) | |
| Bicycle Therapeutics PLC (ADR) | Alethia Young | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 87,000 | 87,000 | - | - | Employee Stock Option (right to buy) | |
| Bicycle Therapeutics PLC (ADR) | Michael Charles Ferguson Hannay | CHIEF PROD & SUPPLY CHAIN OFF | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 87,000 | 87,000 | - | - | Employee Stock Option (right to buy) | |
| Conmed Corp | Patrick J. Beyer | President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 86,355 | 86,355 | - | - | Options To Purchase Common Stock | |
| Ionis Pharma Inc | Brett P. Monia | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 86,263 | 86,263 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ventyx Biosciences Inc | Mark S. Forman | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 85,000 | 85,000 | - | - | Stock Option (Right to Buy) | |
| AMC Entertainment Holdings Inc (Class A) | Sean D. Goodman | EVP, CFO & Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2025 | 84,226 | 156,769 (0%) | 0% | 0 | Class A Common Stock | |
| Janux Therapeutics Inc | Thomas DiRaimondo | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 84,000 | 84,000 | - | - | Stock option (right to buy) | |
| Amicus Therapeutics Inc | Simon Nicolas Reade Harford | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 83,073 | 227,427 (0%) | 0% | 0 | Common Stock | |
| Amicus Therapeutics Inc | Jeff Castelli | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 83,073 | 453,288 (0%) | 0% | 0 | Common Stock | |
| Arcellx Inc | Michelle Gilson | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 82,120 | 82,120 | - | - | Restricted Stock Unit | |
| Assertio Holdings Inc | Mark Reisenauer L. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 81,225 | 81,225 | - | - | Stock Option (right to buy) | |
| Janux Therapeutics Inc | David Campbell | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 81,000 | 298,054 | - | 0 | Common Stock | |
| Janux Therapeutics Inc | Charles M. Winter | Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 80,500 | 80,500 | - | - | Stock option (right to buy) | |
| New Fortress Energy Inc (Class A) | Yunyoung Shin | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2025 | 80,455 | 128,115 (0%) | 0% | 0 | Class A Common Stock | |
| New Fortress Energy Inc (Class A) | Yunyoung Shin | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2025 | 80,455 | 30,883 | - | - | Restricted Stock Units | |
| TeraWulf Inc | Kenneth J. Deane | Chief Acct Officer + Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 80,000 | 80,000 | - | - | Restricted Stock Units | |
| Goosehead Insurance Inc (Class A) | Mark K. Miller | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 80,000 | 80,000 | - | - | Employee Stock Options (right to buy) | |
| Goosehead Insurance Inc (Class A) | Mark E. Jones | Director, Executive Chairman, Ten Percent Owner, Member of 10% owner group | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 80,000 | 80,000 | - | - | Employee Stock Options (right to buy) | |
| NewAmsterdam Pharma Co NV | Louise Kooij | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 80,000 | 80,000 | - | - | Option (right to buy) | |
| Photronics Inc | Kang Jyh Lee | CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 80,000 | 590,850 (0%) | 0% | 0 | COMMON STOCK | |
| Gaming and Leisure Properties Inc | Brandon John Moore | President, COO, and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 78,160 | 311,711 (0%) | 0% | 0 | Common Stock | |
| Pearson PLC (ADR) | Omar P Abbosh | Executive Director,Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 12.96 per share. | 02 Jan 2025 | 77,989 | 384,853 (0%) | 0% | 13.0 | 1,010,979 | Ords 0.25p |
| UDR | Michael D. Lacy | COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 76,360 | 330,655 | - | - | Class 2 LTIP Units | |
| Courtside Grp Inc | James Berk | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 75,071 | 75,071 | - | - | Restricted Stock Units | |
| Marchex Inc (Class B) | Michael Arends A. | Director, Vice Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 75,000 | 75,000 | - | - | Employee Stock Option (right to buy) | |
| Capricor Therapeutics Inc | Anthony J. Bergmann | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| Dyadic Intl Inc, DE | Joseph Hazelton | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 75,000 | 75,000 | - | - | Stock Option | |
| 60 Degrees Pharma Inc | Tyrone Miller | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| Rallybio Corp | Ronald M. Hunt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 73,571 | 73,571 | - | - | Option (Right to Buy) | |
| Rallybio Corp | Robert Hopfner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 73,571 | 73,571 | - | - | Option (Right to Buy) | |
| Dyadic Intl Inc, DE | Mark A. Emalfarb | Director, President and CEO, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 73,111 | 4,730,058 (17%) | 0% | 0 | Common Stock | |
| Perella Weinberg Partners | Peter A. Weinberg | Director, Chairman | Sale of securities on an exchange or to another person at price $ 23.60 per share. | 02 Jan 2025 | 72,866 | 628,755 | - | 23.6 | 1,719,638 | Class A Common Stock |
| JBG SMITH Properties | W. Matthew Kelly | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 72,239 | 1,952,542 | - | - | LTIP Units | |
| AMC Entertainment Holdings Inc (Class A) | Sean D. Goodman | EVP, CFO & Treasurer | 02 Jan 2025 | 70,175 | 140,352 | - | - | Restricted Stock Units | ||
| Rush Street Interactive Inc (Class A) | Einar Roosileht | Chief Information Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 02 Jan 2025 | 70,000 | 2,744,157 | - | 0 | Class V Voting Stock | |
| Rush Street Interactive Inc (Class A) | Einar Roosileht | Chief Information Officer | 02 Jan 2025 | 70,000 | 2,744,157 | - | - | Class A Common Units of Rush Street Interactive, L.P. | ||
| Rush Street Interactive Inc (Class A) | Einar Roosileht | Chief Information Officer | 02 Jan 2025 | 70,000 | 879,260 | - | 0 | Class A Common Stock | ||
| Bentley Systems Inc (Class B) | Keith A. Bentley | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 46.67 per share. | 02 Jan 2025 | 69,573 | 16,705,028 | - | 46.7 | 3,246,812 | Class B Common Stock |
| Amicus Therapeutics Inc | David Michael Clark | Chief People Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 69,228 | 331,195 (0%) | 0% | 0 | Common Stock | |
| Iron Mountain | William L. Meaney | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2025 | 69,131 | 760,375 | - | - | Employee Stock Option (Right to Buy) | |
| Iron Mountain | William L. Meaney | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 36.59 per share. | 02 Jan 2025 | 69,131 | 69,131 (0%) | 0% | 36.6 | 2,529,365 | Common Stock, par value $.01 per share |
| Full House Resorts Inc | Daniel R. Lee | Director, PRESIDENT & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 69,027 | 69,027 | - | - | Employee Stock Option (right to buy) | |
| Easterly Government Properties Inc | Michael P. Ibe | Director, EVP - Dev & Acquisitions | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 68,430 | 68,430 | - | - | LTIP Units | |
| Werewolf Therapeutics Inc | Randi Isaacs | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 68,151 | 68,151 | - | - | Stock Option (right to buy) | |
| Perella Weinberg Partners | Peter A. Weinberg | Director, Chairman | Sale of securities on an exchange or to another person at price $ 23.12 per share. | 02 Jan 2025 | 68,134 | 560,621 | - | 23.1 | 1,575,258 | Class A Common Stock |
| Rallybio Corp | Hui Liu | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 67,857 | 67,857 | - | - | Option (Right to Buy) | |
| Workday (Class A) | David A. Duffield | Ten Percent Owner | 02 Jan 2025 | 67,822 | 42,717,083 | - | - | Class B Common Stock | ||
| Workday (Class A) | David A. Duffield | Ten Percent Owner | 02 Jan 2025 | 67,822 | 170,819 (0%) | 0% | 0 | Class A Common Stock | ||
| Utz Brands Inc (Class A) | Howard A. Friedman | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 67,578 | 262,204 | - | 0 | Class A Common Stock | |
| Dyadic Intl Inc, DE | Jack L. Kaye | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 67,500 | 67,500 | - | - | Stock Option | |
| Dyadic Intl Inc, DE | Patrick K. Lucy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 67,500 | 67,500 | - | - | Stock Option | |
| Dyadic Intl Inc, DE | Arindam Bose | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 67,500 | 67,500 | - | - | Stock Option | |
| NRG Energy | Lawrence S. Coben | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 67,020 | 67,020 | - | - | Relative Performance Stock Units | |
| LXP Industrial Trust | Brendan P. Mullinix | EVP & Chief Investment Officer | Sale or transfer of securities back to the company at price $ 8.01 per share. | 02 Jan 2025 | 65,844 | 587,660 (0%) | 0% | 8.0 | 527,410 | Common Shares |
| Bumble Inc (Class A) | Lidiane S. Jones | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.97 per share. | 02 Jan 2025 | 65,297 | 683,054 | - | 8.0 | 520,417 | Class A Common Stock |
| Palo Alto | Arora Nikesh | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 181.05 per share. | 02 Jan 2025 | 64,607 | 1,098,094 (1%) | 0% | 181.1 | 11,697,420 | Common Stock |
| Cartesian Therapeutics Inc | Blaine Davis | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 64,600 | 64,600 | - | - | Employee Stock Option (right to buy) | |
| Dyadic Intl Inc, DE | Ping W. Rawson | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 64,500 | 64,500 | - | - | Stock Option | |
| Regenxbio Inc | Stephen Pakola | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 64,293 | 215,980 (0%) | 0% | 0 | Common Stock | |
| Regions Financial | Russell K. Zusi | SEVP & CRO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2025 | 64,103 | 250,939 | - | - | Restricted Stock Units | |
| Regions Financial | Russell K. Zusi | SEVP & CRO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2025 | 64,103 | 64,103 (0%) | 0% | 0 | Common Stock | |
| DoorDash | Tony Xu | Director, CHIEF EXECUTIVE OFFICER, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 170.61 per share. | 02 Jan 2025 | 63,930 | 8,018 | - | 170.6 | 10,907,033 | Class A Common Stock |
| TKO (Class A) | Mark S. Shapiro | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2025 | 63,187 | 105,343 | - | 0 | Class A Common Stock | |
| TKO (Class A) | Mark S. Shapiro | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2025 | 63,187 | 189,562 | - | - | Restricted Stock Unit | |
| Janux Therapeutics Inc | Andrew Hollman Meyer | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 63,000 | 63,000 | - | - | Stock option (right to buy) | |
| Amicus Therapeutics Inc | Samantha Prout L. | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 62,715 | 62,715 | - | - | Stock Options (right to buy) | |
| Regenxbio Inc | Mitchell Chan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 62,547 | 62,547 | - | - | Stock Options (Right to buy) | |
| Gaming and Leisure Properties Inc | Desiree A. Burke | CFO and Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 62,528 | 188,601 (0%) | 0% | 0 | Common Stock | |
| Imax Corp | Richard Lewis Gelfond | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2025 | 62,528 | 611,105 (0%) | 0% | 0 | common shares | |
| Imax Corp | Richard Lewis Gelfond | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2025 | 62,528 | 62,529 | - | - | restricted share units | |
| CorMedix Inc | Matthew T. David | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 62,500 | 110,434 (0%) | 0% | 0 | Common Stock | |
| CorMedix Inc | Erin Mistry | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 62,500 | 114,511 (0%) | 0% | 0 | Common Stock | |
| Imax Corp | Richard Lewis Gelfond | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2025 | 61,192 | 637,340 (1%) | 0% | 0 | common shares | |
| Imax Corp | Richard Lewis Gelfond | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2025 | 61,192 | 123,386 | - | - | restricted share units | |
| Solaredge Tech Inc | Uri Bechor | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 60,810 | 150,810 | - | - | Performance Stock Units | |
| Solaredge Tech Inc | Ariel Porat | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 60,810 | 60,810 | - | - | Performance Stock Units | |
| Weatherford Intl PLC - Ordinary Shares - New | Scott C. Weatherholt | EVP, GC & CCO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2025 | 60,570 | 0 | - | - | 2021 Program Performance Share Units | |
| Weatherford Intl PLC - Ordinary Shares - New | Scott C. Weatherholt | EVP, GC & CCO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2025 | 60,570 | 185,589 (0%) | 0% | 0 | Ordinary Shares | |
| UDR | Joseph D. Fisher | President, CFO & CIO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 60,369 | 608,489 | - | - | Class 2 LTIP Units | |
| Courtside Grp Inc | Jay Krigsman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 60,362 | 60,362 | - | - | Restricted Stock Units | |
| Werewolf Therapeutics Inc | Timothy W. Trost | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 60,358 | 60,358 | - | - | Stock Option (right to buy) | |
| Sotherly Hotels Inc | Andrew M. Sims | Director, Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 60,000 | 826,909 (5%) | 0% | - | Common Stock | |
| Capricor Therapeutics Inc | Karen G. Krasney | EVP, GENERAL COUNSEL | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| NRG Energy | Robert J. Gaudette | Exec VP, NRG Business | Sale of securities on an exchange or to another person at price $ 91.41 per share. | 02 Jan 2025 | 60,000 | 64,448 (0%) | 0% | 91.4 | 5,484,600 | Common Stock, par value $.01 per share |
| TuHURA Biosciences Inc | James S.J. Manuso | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 59,590 | 59,590 | - | - | Options (Right to Buy) | |
| JBG SMITH Properties | George Laucks Xanders | Chief Investment Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 59,479 | 537,327 | - | - | AO LTIP | |
| Regenxbio Inc | Olivier Danos | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 59,347 | 231,800 (0%) | 0% | 0 | Common Stock | |
| Gaming and Leisure Properties Inc | Matthew R. Demchyk | SVP, Chief Investment Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 58,620 | 114,421 (0%) | 0% | 0 | Common Stock | |
| Gaming and Leisure Properties Inc | Steven L. Ladany | SVP Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 58,620 | 139,282 (0%) | 0% | 0 | Common Stock | |
| JBG SMITH Properties | Madhumita Moina Banerjee | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 58,550 | 557,766 | - | - | AO LTIP | |
| Peabody Energy Corp - Ordinary Shares New | James C. Grech | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 58,125 | 331,856 (0%) | 0% | 0 | Common Stock | |
| CarMax | James R. Lyski | EVP, Chief Growth & Strat Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 63.04 per share. | 02 Jan 2025 | 57,986 | 80,789 (0%) | 0% | 63.0 | 3,655,437 | Common Stock |
| CarMax | James R. Lyski | EVP, Chief Growth & Strat Off | Sale of securities on an exchange or to another person at price $ 81.35 per share. | 02 Jan 2025 | 57,986 | 22,803 (0%) | 0% | 81.3 | 4,717,161 | Common Stock |
| CarMax | James R. Lyski | EVP, Chief Growth & Strat Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2025 | 57,986 | 0 | - | - | Stock Options (Right to Buy) | |
| Utz Brands Inc (Class A) | Cary Devore | EVP, Chief Op & Transform Ofc | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 57,694 | 482,672 | - | 0 | Class A Common Stock | |
| Cartesian Therapeutics Inc | Carsten Brunn | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 57,500 | 221,367 (0%) | 0% | 0 | Common Stock | |
| Sotherly Hotels Inc | David R. Folsom | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 57,000 | 114,095 (0%) | 0% | - | Common Stock | |
| Ventas | A. Cafaro Debra | Director, Chairman and CEO | Grant, award, or other acquisition of securities at price $ 57.96 per share. | 02 Jan 2025 | 56,935 | 1,043,652 (0%) | 0% | 58.0 | 3,299,953 | Common Stock |
| Cartesian Therapeutics Inc | Milos Miljkovic | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 56,000 | 56,000 | - | - | Employee Stock Option (right to buy) | |
| Arcellx Inc | Rami Elghandour | Director, SEE REMARKS | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2025 | 55,459 | 124,712 | - | 0 | Common Stock | |
| Arcellx Inc | Rami Elghandour | Director, SEE REMARKS | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2025 | 55,459 | 110,918 | - | - | Restricted Stock Unit | |
| Courtside Grp Inc | Ramin Arani | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 55,113 | 55,113 | - | - | Restricted Stock Units | |
| Gaming and Leisure Properties Inc | Peter M. Carlino | Director, Chairman and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 55,000 | 55,000 | - | - | LTIP Units | |
| LXP Industrial Trust | Brendan P. Mullinix | EVP & Chief Investment Officer | Grant, award, or other acquisition of securities at price $ 8.01 per share. | 02 Jan 2025 | 54,940 | 807,395 (0%) | 0% | 8.0 | 440,069 | Common Shares |
| Easterly Government Properties Inc | Darrell W. Crate | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 54,876 | 54,876 | - | - | LTIP Units | |
| WEC Energy | Scott J. Lauber | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 54,319 | 54,319 | - | - | Stock Option (right to buy) | |
| Phreesia Inc | Evan Roberts | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 53,990 | 782,866 (2%) | 0% | 0 | Common Stock | |
| Phreesia Inc | David Linetsky | SVP, Life Sciences | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 53,990 | 242,344 (0%) | 0% | 0 | Common Stock | |
| Phreesia Inc | Balaji Gandhi | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 53,990 | 151,704 (0%) | 0% | 0 | Common Stock | |
| Assertio Holdings Inc | Mark Reisenauer L. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 53,750 | 53,750 (0%) | 0% | 0 | Common Stock | |
| Iron Mountain | William L. Meaney | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 104.68 per share. | 02 Jan 2025 | 53,565 | 15,566 (0%) | 0% | 104.7 | 5,607,345 | Common Stock, par value $.01 per share |
| Monte Rosa Therapeutics Inc | Edmund Dunn | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 53,400 | 53,400 | - | - | Stock Option (Right to Buy) | |
| Arcellx Inc | Rami Elghandour | Director, SEE REMARKS | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2025 | 53,097 | 177,809 | - | 0 | Common Stock | |
| Arcellx Inc | Rami Elghandour | Director, SEE REMARKS | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2025 | 53,097 | 53,098 | - | - | Restricted Stock Unit | |
| UDR | Thomas W. Toomey | Director, Chairman and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 52,824 | 1,054,628 | - | - | Class 2 LTIP Units | |
| Arcellx Inc | Christopher Heery | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 52,258 | 52,258 | - | - | Restricted Stock Unit | |
| Arcellx Inc | Christopher Heery | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 52,258 | 52,258 | - | - | Restricted Stock Unit | |
| Imax Corp | Richard Lewis Gelfond | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2025 | 51,383 | 576,992 (0%) | 0% | 0 | common shares | |
| Imax Corp | Richard Lewis Gelfond | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2025 | 51,383 | 0 | - | - | restricted share units | |
| TuHURA Biosciences Inc | Robert E. Hoffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 51,275 | 51,275 | - | - | Options (Right to Buy) | |
| TuHURA Biosciences Inc | Alan List | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 51,275 | 51,275 | - | - | Options (Right to Buy) | |
| TKO (Class A) | Nick Khan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2025 | 51,225 | 196,508 | - | 0 | Class A Common Stock | |
| TKO (Class A) | Nick Khan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2025 | 51,225 | 102,451 | - | - | Restricted Stock Unit | |
| Nuvectis Pharma Inc | Michael J. Carson | Vice President, Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 51,000 | 138,918 | - | 0 | Common Stock | |
| American Homes 4 Rent (Class A) | Bryan A. Smith | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 50,885 | 176,465 (0%) | 0% | 0 | Class A Common Shares | |
| MFA Fin Inc | Michael C. Roper | Sr VP & Chief Financial Ofcr | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 50,512 | 197,023 | - | - | Phantom Shares | |
| Opus Genetics Inc | James S.J. Manuso | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 50,222 | 182,259 | - | - | Common Stock | |
| Copart | Matt Blunt | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 28.02 per share. | 02 Jan 2025 | 50,000 | 50,000 (0%) | 0% | 28.0 | 1,401,125 | Common Stock |
| Copart | Matt Blunt | Director | Sale of securities on an exchange or to another person at price $ 57.66 per share. | 02 Jan 2025 | 50,000 | 0 (0%) | 0% | 57.7 | 2,883,000 | Common Stock |
| Copart | Matt Blunt | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2025 | 50,000 | 0 | - | - | Stock Option (right to buy) | |
| DoorDash | Stanley Tang | Director | Other type of transaction at price $ 0.00 per share. | 02 Jan 2025 | 50,000 | 50,000 | - | 0 | Class A Common Stock | |
| DoorDash | Stanley Tang | Director | Other type of transaction at price $ 0.00 per share. | 02 Jan 2025 | 50,000 | 4,337,215 | - | - | Class B Common Stock | |
| Arteris Inc | K. Charles Janac | Director, President and CEO, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 10.98 per share. | 02 Jan 2025 | 50,000 | 9,957,691 | - | 11.0 | 548,995 | Common Stock |
| Capricor Therapeutics Inc | Frank Litvack | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Dyadic Intl Inc, DE | Seth J. Herbst | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 50,000 | 50,000 | - | - | Stock Option | |
| Equillium Inc | Daniel M. Bradbury | Director, EXECUTIVE CHAIRMAN, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 50,000 | 50,000 | - | - | Employee Stock Option (right to buy) | |
| Hayward Holdings Inc | Kevin P. Holleran | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.40 per share. | 02 Jan 2025 | 50,000 | 572,799 | - | 1.4 | 70,000 | Common Stock |
| Hayward Holdings Inc | Kevin P. Holleran | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 15.32 per share. | 02 Jan 2025 | 50,000 | 522,799 | - | 15.3 | 766,030 | Common Stock |
| Hayward Holdings Inc | Kevin P. Holleran | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2025 | 50,000 | 3,138,571 | - | - | Stock Options (Right to Buy) | |
| Rapid7 Inc | Corey E. Thomas | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.77 per share. | 02 Jan 2025 | 50,000 | 481,469 (0%) | 0% | 9.8 | 488,500 | COMMON STOCK |
| Rapid7 Inc | Corey E. Thomas | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2025 | 50,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Global Indemnity Grp LLC (Class A) | Joseph W. Brown | Director, Chief Executive | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 50,000 | 450,000 | - | - | Option to Purchase Class A Common Shares (right to buy) | |
| JBG SMITH Properties | George Laucks Xanders | Chief Investment Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 49,883 | 520,357 | - | - | LTIP Units | |
| Courtside Grp Inc | Patrick Wachsberger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 49,864 | 49,864 | - | - | Restricted Stock Units | |
| LXP Industrial Trust | Beth Boulerice | EVP, CFO and Treasurer | Sale or transfer of securities back to the company at price $ 8.01 per share. | 02 Jan 2025 | 49,383 | 264,313 (0%) | 0% | 8.0 | 395,558 | Common Shares |
| Xcel Energy | Robert C. Frenzel | Director, Chairman, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 49,357 | 347,331 (0%) | 0% | 0 | Common Stock | |
| Payoneer Global Inc | Tsafi Goldman | Chief Legal & Regulatory Ofcr | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 02 Jan 2025 | 49,350 | 838,098 | - | 2.9 | 143,115 | Common Stock |
| Payoneer Global Inc | Tsafi Goldman | Chief Legal & Regulatory Ofcr | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2025 | 49,350 | 82,250 | - | - | Stock Options (Right to buy) | |
| JBG SMITH Properties | Madhumita Moina Banerjee | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 49,103 | 267,329 | - | - | LTIP Units | |
| Gilead Sciences | Dietmar Berger | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 48,975 | 48,975 | - | - | Restricted Stock Unit | |
| Rush Street Interactive Inc (Class A) | Einar Roosileht | Chief Information Officer | Sale of securities on an exchange or to another person at price $ 14.04 per share. | 02 Jan 2025 | 48,968 | 830,292 | - | 14.0 | 687,726 | Class A Common Stock |
| Brand Engagement Network Inc | Jon Leibowitz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 48,861 | 88,861 | - | 0 | Common Stock | |
| Fastenal | Daniel L. Florness | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 48,611 | 48,611 | - | - | Employee Stock Option (Right to Buy) | |
| Sunopta Inc | Brian W. Kocher | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2025 | 48,135 | 48,135 (0%) | 0% | - | Common Shares | |
| Sunopta Inc | Brian W. Kocher | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2025 | 48,135 | 96,269 | - | - | Restricted Stock Units | |
| Silence Therapeutics PLC (ADR) | James Lawrence Ede-Golightly | Director | 02 Jan 2025 | 48,000 | 48,000 | - | - | Share Option (Right to Buy) | ||
| Silence Therapeutics PLC (ADR) | Michael Harvey Davidson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 48,000 | 48,000 | - | - | Share Option (Right to Buy) | |
| Silence Therapeutics PLC (ADR) | David Jakob Lemus | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 48,000 | 48,000 | - | - | Share Option (Right to Buy) | |
| Quince Therapeutics Inc | David A. Lamond | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 47,587 | 47,587 | - | - | Director Stock Option (right to buy) | |
| Sila Realty Trust Inc | Michael A. Seton | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 47,415 | 217,069 | - | 0 | Common Stock | |
| Cartesian Therapeutics Inc | Metin Kurtoglu | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 47,400 | 47,400 | - | - | Employee Stock Option (right to buy) | |
| Cartesian Therapeutics Inc | Christopher M. Jewell | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 47,400 | 47,400 | - | - | Employee Stock Option (right to buy) | |
| Cartesian Therapeutics Inc | Emily English | Chief Operations Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 47,400 | 47,400 | - | - | Employee Stock Option (right to buy) | |
| MFA Fin Inc | Harold E. Schwartz | Senior Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 47,354 | 239,360 | - | - | Phantom Shares | |
| UiPath Inc (Class A) | Ashim Gupta | COO & CFO | Sale of securities on an exchange or to another person at price $ 13.06 per share. | 02 Jan 2025 | 47,227 | 856,538 | - | 13.1 | 616,889 | Class A Common Stock |
| Payoneer Global Inc | Tsafi Goldman | Chief Legal & Regulatory Ofcr | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.74 per share. | 02 Jan 2025 | 47,000 | 788,748 | - | 2.7 | 128,780 | Common Stock |
This section tracks all disclosures required by the U.S. Securities and Exchange Commission (SEC) under the Securities Exchange Act of 1934, particularly those related to Section 16 and Rule 10b-5, which govern insider trading activities in the U.S. market. These disclosures are made by corporate insiders, including executives, officers, directors, significant employees, and large shareholders, who are buying and selling stock in their own companies. You can search and filter within these results. You can also sort the information by clicking on the column headers.